Close this search box.

BMS’s patent cliff challenge, and Congress targets China biotech: BioCentury’s latest podcast

Plus: IPO sentiment and the innovation behind 2023’s series A companies

By Jeff Cranmer, Executive Editor

February 6, 2024 2:02 AM UTC

As it approaches a steep patent cliff, Bristol Myers Squibb Co. (NYSE:BMY) is charting its course to bridge a transition period and return to growth. On the latest BioCentury This Week podcast, BioCentury’s editors assess the pharma’s pipeline and recent M&A, outlining the clinical and commercial successes the company needs to navigate the next few years.  

The editors also discuss what’s behind bills in Washington that target four Chinese companies identified by Congress as “biotechnology companies of concern” and the legislation’s chances to become law. The companies — BGI Genomics Co. Ltd. (SZSE:300676), MGI Tech Co. Ltd. (Shanghai:688114), WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) and WuXi Biologics Inc. (HKEX:2269), which together have lost $20 billion in market cap as the bills have gained traction — deny the allegations in the bills.

Finally, the team talks about the latest biotech IPOs — from neuropsychiatry company Alto Neuroscience Inc. (NYSE:ANRO) and obesity and diabetes play Fractyl Health Inc. (NASDAQ:GUTS) — and the innovation behind last year’s biotech series A raisers, including technology for mitophagy induction, epigenome editing and delivery vectors.

Join BioCentury, BayHelix and McKinsey March 4-6 in Singapore for the third East-West Biopharma Summit. For information on how to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact BioCentury at